On September 24, 2025, Knowledge Ecology International submitted comments to the NIH regarding the “Prospective Grant of an NCI Exclusive Patent License: Use of Anti-Mesothelin Immunotoxins for the Treatment of Mesothelin-Expressing Cancers” (90 FR 43617) to Lysin Therapeutics.
Although the notice states that Lysin Therapeutics is based in Silver Spring, Maryland, a query of the Maryland state Business Entity Search for “Lysin Therapeutics” returns no results. Indeed, as highlighted in our comments,
“there is almost no publicly available information about Lysin Therapeutics, severely limiting the intended utility of the public notice and comment period for an exclusive license. A Google search of “Lysin Therapeutics” returns only results related to the instant proposed exclusive license or technology news about therapeutics involving lysins more broadly. A search of “Lysin Therapeutics” and “Silver Spring” returns only results about this license.”
This dearth of information hamstrings the public’s ability to comment on this prospective exclusive license and to assess whether exclusivity is warranted.
KEI’s full comments are available here: KEI-Comments-NIH-License-Lysin-24Sept2025